PortalPublikationenLate treatment-related mortality versus competing causes of ...

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Standard

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. / Schetelig, Johannes; de Wreede, Liesbeth C; van Gelder, Michel; Koster, Linda; Finke, Jürgen; Niederwieser, Dietger; Beelen, Dietrich; Mufti, G J; Platzbecker, Uwe; Ganser, Arnold; Heidenreich, Silke; Maertens, Johan; Socié, Gerard; Brecht, Arne; Stelljes, Matthias; Kobbe, Guido; Volin, Liisa; Nagler, Arnon; Vitek, Antonin; Luft, Thomas; Ljungman, Per; Yakoub-Agha, Ibrahim; Robin, Marie; Kröger, Nicolaus.

in: LEUKEMIA, Jahrgang 33, Nr. 3, 03.2019, S. 686-695.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schetelig, J, de Wreede, LC, van Gelder, M, Koster, L, Finke, J, Niederwieser, D, Beelen, D, Mufti, GJ, Platzbecker, U, Ganser, A, Heidenreich, S, Maertens, J, Socié, G, Brecht, A, Stelljes, M, Kobbe, G, Volin, L, Nagler, A, Vitek, A, Luft, T, Ljungman, P, Yakoub-Agha, I, Robin, M & Kröger, N 2019, 'Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia', LEUKEMIA, Jg. 33, Nr. 3, S. 686-695. https://doi.org/10.1038/s41375-018-0302-y

APA

Schetelig, J., de Wreede, L. C., van Gelder, M., Koster, L., Finke, J., Niederwieser, D., Beelen, D., Mufti, G. J., Platzbecker, U., Ganser, A., Heidenreich, S., Maertens, J., Socié, G., Brecht, A., Stelljes, M., Kobbe, G., Volin, L., Nagler, A., Vitek, A., ... Kröger, N. (2019). Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. LEUKEMIA, 33(3), 686-695. https://doi.org/10.1038/s41375-018-0302-y

Vancouver

Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D et al. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. LEUKEMIA. 2019 Mär;33(3):686-695. https://doi.org/10.1038/s41375-018-0302-y

Bibtex

@article{e6037907c390470ebedfc4f498e6bbcb,
title = "Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia",
abstract = "The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%. Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients <45-year old and 63% for patients ≥65-year old at alloHCT. Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older patients, 31% of NRM-deaths could be attributed to population mortality. Favorable post-alloHCT long-term survival was seen; however, excess mortality-risk for all age groups was shown compared to the general population. A substantial part of total NRM for older patients was attributable to population mortality, information which aids the balanced explanation of post-HCT risk and helps improve long-term care.",
keywords = "Journal Article",
author = "Johannes Schetelig and {de Wreede}, {Liesbeth C} and {van Gelder}, Michel and Linda Koster and J{\"u}rgen Finke and Dietger Niederwieser and Dietrich Beelen and Mufti, {G J} and Uwe Platzbecker and Arnold Ganser and Silke Heidenreich and Johan Maertens and Gerard Soci{\'e} and Arne Brecht and Matthias Stelljes and Guido Kobbe and Liisa Volin and Arnon Nagler and Antonin Vitek and Thomas Luft and Per Ljungman and Ibrahim Yakoub-Agha and Marie Robin and Nicolaus Kr{\"o}ger",
year = "2019",
month = mar,
doi = "10.1038/s41375-018-0302-y",
language = "English",
volume = "33",
pages = "686--695",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

AU - Schetelig, Johannes

AU - de Wreede, Liesbeth C

AU - van Gelder, Michel

AU - Koster, Linda

AU - Finke, Jürgen

AU - Niederwieser, Dietger

AU - Beelen, Dietrich

AU - Mufti, G J

AU - Platzbecker, Uwe

AU - Ganser, Arnold

AU - Heidenreich, Silke

AU - Maertens, Johan

AU - Socié, Gerard

AU - Brecht, Arne

AU - Stelljes, Matthias

AU - Kobbe, Guido

AU - Volin, Liisa

AU - Nagler, Arnon

AU - Vitek, Antonin

AU - Luft, Thomas

AU - Ljungman, Per

AU - Yakoub-Agha, Ibrahim

AU - Robin, Marie

AU - Kröger, Nicolaus

PY - 2019/3

Y1 - 2019/3

N2 - The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%. Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients <45-year old and 63% for patients ≥65-year old at alloHCT. Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older patients, 31% of NRM-deaths could be attributed to population mortality. Favorable post-alloHCT long-term survival was seen; however, excess mortality-risk for all age groups was shown compared to the general population. A substantial part of total NRM for older patients was attributable to population mortality, information which aids the balanced explanation of post-HCT risk and helps improve long-term care.

AB - The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%. Overall survival probability was 53% at 2 years and 35% at 10 years post-alloHCT. Survival probability at 5 years from the 2-year landmark was 88% for patients <45-year old and 63% for patients ≥65-year old at alloHCT. Cumulative incidence of nonrelapse mortality (NRM) for patients <45-year old at transplant was 7% rising to 25% for patients aged ≥65. For older patients, 31% of NRM-deaths could be attributed to population mortality. Favorable post-alloHCT long-term survival was seen; however, excess mortality-risk for all age groups was shown compared to the general population. A substantial part of total NRM for older patients was attributable to population mortality, information which aids the balanced explanation of post-HCT risk and helps improve long-term care.

KW - Journal Article

U2 - 10.1038/s41375-018-0302-y

DO - 10.1038/s41375-018-0302-y

M3 - SCORING: Journal article

C2 - 30573777

VL - 33

SP - 686

EP - 695

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 3

ER -